EGF and cancer: Therefore, we compared the effect of SKI-606 with Iressa, a tyrosine kinase inhibitor (TKI) of EGF and ErbB2 receptors which is presently in phase II clinical trial for patients with recurrent or metastatic cervical carcinomas [26], in HeLa and SiHa cancer cell lines.